Diltiazem, vasopressin과 3-in-1 정맥영양의 물리적 배합적합성
The Physical Compatibility of Diltiazem and Vasopressin with usage of 3-in-1 Parenteral Nutrition Admixtures
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : The hospitalized patients requiring parenteral nutrition (PN) often need to receive intravenous medications as well, as noted in some cases. The Y-site administration is occasionally necessary, but some physicochemical incompatibilities can occur between the medications and PN. The absence of drug compatibility information with 3-in-1 parenteral nutrition admixture (PNA) has been problematic in this case. The infusion of a precipitate or destabilized emulsion can be harmful for the patients. Therefore, the aim of this study was to evaluate the physical compatibility of 2 selected drugs during a simulated Y-site injection and additive condition into a 3-in-1 PNA. Methods : 3-in-1 PNA (OMAFONE Inj 986 mL) were tested with two drugs (diltiazem, vasopressin). PNAs and drugs were mixed in 1:1(v/v) proportions and the compatibility was assessed at the time of mixing and after 1, 24, 48 and 72 hours. Chiefly, the assessment of potential precipitation and the emulsion stability was performed by a subvisual particle counting an, through visual examinations and a measurement of globule size distribution. Results : In all samples we did not observe changes on the visual examinations. It is noted that the oil droplet mean size changes over 1.5 μm are to exceed 2% in the Y-site samples of diltiazem and vasopressin within 24 hours. In particular, these samples of vasopressin did not disappear until after a 72 hours timeframe. However, the globule size distribution via a dynamic light scattering are maintained at 200-300 nm during the experimental period. Conclusions : The present study experiment noted the compatibility of 1 commercially available PNA and 2 medications. The extrapolation of compatibility data based on conditions applicable for other products is not recommended. It is noted that a different outcome can also be a result of differences in the methodology or interpretation of the results. Finally, we recommend that a filter is concerned primarily with the protection of patients from the effects of an infusion of particulates and chemical precipitates. The appropriate use of this complex therapy is able to maximize the clinical benefit while minimizing the potential risks for adverse events.
Abstract
Background : The hospitalized patients requiring parenteral nutrition (PN) often need to receive intravenous medications as well, as noted in some cases. The Y-site administration is occasionally necessary, but some physicochemical incompatibilities can occur between the medications and PN. The absence of drug compatibility information with 3-in-1 parenteral nutrition admixture (PNA) has been problematic in this case. The infusion of a precipitate or destabilized emulsion can be harmful for the patients. Therefore, the aim of this study was to evaluate the physical compatibility of 2 selected drugs during a simulated Y-site injection and additive condition into a 3-in-1 PNA. Methods : 3-in-1 PNA (OMAFONE Inj 986 mL) were tested with two drugs (diltiazem, vasopressin). PNAs and drugs were mixed in 1:1(v/v) proportions and the compatibility was assessed at the time of mixing and after 1, 24, 48 and 72 hours. Chiefly, the assessment of potential precipitation and the emulsion stability was performed by a subvisual particle counting an, through visual examinations and a measurement of globule size distribution. Results : In all samples we did not observe changes on the visual examinations. It is noted that the oil droplet mean size changes over 1.5 μm are to exceed 2% in the Y-site samples of diltiazem and vasopressin within 24 hours. In particular, these samples of vasopressin did not disappear until after a 72 hours timeframe. However, the globule size distribution via a dynamic light scattering are maintained at 200-300 nm during the experimental period. Conclusions : The present study experiment noted the compatibility of 1 commercially available PNA and 2 medications. The extrapolation of compatibility data based on conditions applicable for other products is not recommended. It is noted that a different outcome can also be a result of differences in the methodology or interpretation of the results. Finally, we recommend that a filter is concerned primarily with the protection of patients from the effects of an infusion of particulates and chemical precipitates. The appropriate use of this complex therapy is able to maximize the clinical benefit while minimizing the potential risks for adverse events.
참고문헌 (23)
- McClave SA, "Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P. E.N.)", JPEN J Parenter Enteral Nutr, 33, pp.277~316 (2009)[DOI]
- Heyland DK, "Total parenteral nutrition in the critically ill patient: a meta-analysis", JAMA, 280, pp.2013~2019 (1998)[DOI]
- Ziegler TR, "Parenteral nutrition in the critically ill patient", N Engl J Med, 361, pp.1088~1097 (2009)[DOI]
- Alberda C, "The relationship between nutritional intake and clinical outcomes in critically ill patients: results of an international multicenter observational study", Intensive Care Med, 35, pp.1728~1737 (2009)[DOI]
- Tucker A, "Standards of practice for nutrition support pharmacists task force; American society for parenteral and enteral nutrition. American society for parenteral and enteral nutrition (A.S.P.E.N.) standards of practice for nutrition support pharmacists", Nutr Clin Pract, 30(1), pp.139~146 (2015)[DOI]
- Mirtallo J, "Task force for the revision of safe practices for parenteral nutrition. Safe practices for parenteral nutrition", JPEN J Parenter Enteral Nutr, 28(6), pp.S39~S70 (2004)[DOI]
- Dudrick SJ, "Historical highlights of the development of total parenteral nutrition", Surg Clin North Am, 91(3), pp.693~717 (2011)[DOI]
- Allwood MC, "Compatibility and stability of additives in parenteral nutrition admixtures", Nutrition, 14(9), pp.697~706 (1998)[DOI]
- Driscoll DF, "Total nutrient admixtures: theory and practice", Nutr Clin Pract, 10(3), pp.114~119 (1995)[DOI]
- Trissel LA, "Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration", Am J Health Syst Pharm, 54(11), pp.1295~1300 (1997)
- Trissel LA, "Compatibility of medications with 3-in-1 parenteral nutrition admixtures", JPEN J Parenter Enteral Nutr, 23(2), pp.67~74 (1999)[DOI]
- Fox LM, "Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration", Am J Health Syst Pharm, 70(6), pp.520~524 (2013)[DOI]
- Newton DW, "Y-site Compatibility of intravenous drugs with parenteral nutrition", JPEN J Parenter Enteral Nutr, 37(3), pp.297~299 (2013)[DOI]
- Bouchoud L, "Compatibility of intravenous medications with parenteral nutrition: in Vitro evaluation", JPEN J Parenter Enteral Nutr, 37(3), pp.416~424 (2013)[DOI]
- Staven V, "Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents", J Pharm Pharmacol, 69(4), pp.448~462 (2017)[DOI]
- Bozzetti F, "The ESPEN clinical practice guidelines on parenteral nutrition: Present status and perspectives for future research", Clin Nutr, 285(4), pp.359~364 (2009)
- Knowles JB, "Pulmonary deposition of calcium phosphate crystals as a complication of home total parenteral nutrition", JPEN J Parenter Enteral Nutr, 13, pp.209~213 (1989)[DOI]
- McNearney T, "Total parenteral nutrition associated crystalline precipitates resulting in pulmonary artery occlusions and alveolar granulomas", Dig Dis Sci, 48, pp.1352~1354 (2003)[DOI]
- Bradley JS, "Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events", Pediatrics, 123(4), pp.e609~e613 (2009)[DOI]
- Newton DW, "Calcium and phosphate compatibility: Revisited again", Am J Health-Syst Pharm, 65, pp.73~80 (2008)[DOI]
- "Globule size distribution in lipid injectable emulsions (Chapter <729>)", pp.4863~4864 (2017)
- Driscoll DF, "Stability and compatibility assessment techniques for total parenteral nutrition admixtures: Setting the bar according to pharmacopeial standards", Curr Opin Clin Nutr Metab Care, 8(3), pp.297~303 (2005)[DOI]
- Agnieszka Wi cek, "Zeta potential. Effective diameter and multimodal size distribution in oil", water emulsion, 1999, pp.159, 253~261